Johnson & Johnson (NYSE: JNJ) has announced positive results from the Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) ...

About duvakitug Duvakitug is a potential best-in-class human IgG1-λ2 monoclonal antibody that targets tumor necrosis factor (TNF)-like ligand 1A (TL1A), also known as TNF superfamily member 15 ...

Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...

Tampa Bay Lightning forward Michael Eyssimont was diagnosed with Crohn's disease eight years ago at the age of 21. Since then ...

There is no cure for IBD, meaning Michelle must manage her condition daily while raising her three children, but she remains ...

Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug ...

Johnson & Johnson (JNJ) said on Friday that its late-stage study of TREMFYA as an induction therapy for adults with ...

Iterative Health will present five abstracts at the European Crohn’s & Colitis Organization (ECCO) meeting in Berlin, Germany ...

Rusfertide: Protagonist held an in-person PV Day on February 6, 2025, in New York; The topline data for the Phase 3 VERIFY study in PV, which ...

Data presented at key congresses in North America and EuropeCAMBRIDGE, United Kingdom, Feb. 21, 2025 (GLOBE NEWSWIRE) -- ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDItm for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference ...